ARJ Infusion SERVICES *Specialty Pharmacy & High-Tech Nursing*

FAX completed form to ARJ (877) 451-8955
Intake Specialist (866) 451-8804
referral@arjinfusion.com
arjinfusion.com/referrals

Entyvio Standing Order Form

Patient Information

Patient Name: _____ Date: _____

Physician: _____ Primary Diagnosis: _____

Allergies: _____ DOB: _____ Ht: _____ in / cm Wt : _____ lb / kg

Initiate the following orders: *ARJ policy and protocol to be provided upon request.*

Medication	Maintenance Dosing	Directions	Quantity/Refills
☒ Entyvio	☒ 300 mg/ 250 mL NS IV every 8 weeks	☒ Infuse per manufacturer guidelines	Dispense: 1 month supply on all selected medications Refill x12 months unless otherwise noted ☐ *Other:* _____

☒ RN to start peripheral IV or use existing CVC. RN to administer catheter flushing per ARJ Policy and Procedure

☐ **Give premedication 30 minutes prior to infusion** *(Note: If nothing is checked, no premeds will be given)*

Diphenhydramine: ☐ 25-50 mg po **OR** ☐ 50 mg IV diluted in D5W or NS 50-100mL, infuse over 10-15 mins.

Antihistamine: ☐ Fexofenadine 180 mg po **OR** ☐ Cetirizine 10 mg po

Methylprednisolone: ☐ 125 mg slow IV push over 5 mins. **OR** ☐ _____ mg slow IV push over 5 mins.

Acetaminophen: ☐ 325-650 mg po **OR** ☐ _____ mg po

☒ Flush line with NS 30 mL post infusion.

☒ RN to educate patient on possible side effects, allergic reactions, and when to contact physician.

☒ RN to instruct patient to hydrate pre/post infusion. RN to instruct patient to take Diphenhydramine 25-50 mg po and Acetaminophen 325-650 mg po every 4-6 hours for 24-48 hours as needed to prevent/treat post infusion headache.

☐ Other: _____

Adverse Reaction Orders: *(Dispense 1 dose of each medication below)*

In the event of infusion reaction (*fever, dyspnea, rash, increased BP or HR*) the following orders will be followed and physician will be notified.

Note: For mild reactions, patient may be treated, and infusion resumed at a slower rate.

☒ **STOP** infusion. Infuse D5W or NS at 20 mL/hr to keep line open, may increase to 100-250 mL/hr for hydration. May give the following if stopping infusion does not resolve symptoms:

☒ **Diphenhydramine**
50 mg IV diluted in D5W or NS 50-100 mL, infused over 10-15 minutes or 50 mg/10 mL NS IV push over 2-3 minutes, as tolerated.

☒ **Methylprednisolone**
125 mg (**OR** _____ mg) slow IV push over 5 minutes.

☒ **Acetaminophen**
325-650 mg (**OR** _____ mg) po at onset of symptoms.

☒ **Ondansetron**: 4 mg slow IV push over 5 minutes or 4 mg ODT.

☒ **Epinephrine** pen by weight for use IM or SQ in anaphylactic reaction. May repeat one time. EMS/911 will be called if used.

By signing I certify that the use of the indicated treatment is medically necessary and I will be supervising the patient's treatment.
ARJ Infusion Services has my permission to contact the patient's health plan to obtain any authorizations necessary to enable it to receive payment for services.

_____ Date: _____ | _____ Date: _____

Physician Signature Required - Substitution Permitted ***Physician Signature Required - Dispense as Written***

Confidential Health Information: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization and under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure and confidential manner. Re-disclosure of this information is prohibited by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state law. Important Warning: This message is intended for the use of the person or entity to who it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any discrimination, distribution, or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately.